A novel series of pyridazinone-functionalized phenylalanine analogues was prepared and evaluated for inhibition of cellular adhesion mediated by alpha(4)beta(1)/VCAM-1 and alpha(4)beta(7)/MAdCAM-1 interactions. Concise syntheses were developed and applied for exploration of structure-activity relationships pertaining to the pyridazinone ring as well as the N-acyl phenylalanine scaffold. Potent dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) were generated from an amide subseries; antagonists selective for alpha(4)beta(7) were identified from urea and carbamate-based subseries. The pharmacokinetic properties of selected members of the series have been determined in rats and demonstrate that the use of ester prodrugs and alterations to the amide linkage can lead to improved oral bioavailability in this series. An alpha(4),beta(7)-selective member of the carbamate subseries (36c), upon oral admininstration, demonstrated in vivo efficacy in the mouse DSS colitis model.
Journal article
Synthesis and Biological Evaluation of Novel Pyridazinone-Based α4 Integrin Receptor Antagonists
Journal of medicinal chemistry, v 49(11), pp 3402-3411
01 Jun 2006
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Metrics
Details
- Title
- Synthesis and Biological Evaluation of Novel Pyridazinone-Based α4 Integrin Receptor Antagonists
- Creators
- Yong Gong - Johnson & Johnson (United States)J. Kent Barbay - Johnson & Johnson (United States)Alexey B. Dyatkin - Johnson & Johnson (United States)Tamara A. Miskowski - Johnson & Johnson (United States)Edward S. Kimball - Johnson & Johnson (United States)Stephen M. Prouty - Johnson & Johnson (United States)M. Carolyn Fisher - Johnson & Johnson (United States)Rosemary J. Santulli - Johnson & Johnson (United States)Craig R. Schneider - Johnson & Johnson (United States)Nathaniel H. Wallace - Johnson & Johnson (United States)Scott A. Ballentine - Johnson & Johnson (United States)William E. Hageman - Johnson & Johnson (United States)John A. Masucci - Johnson & Johnson (United States)Bruce E. Maryanoff - Johnson & Johnson (United States)Bruce P. Damiano - Johnson & Johnson (United States)Patricia ANDRADE-GORDON - Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh & McKean Roads, P.O. Box 776,Spring House, Pennsylvania 19477Dennis J. Hlasta - Johnson & Johnson (United States)Pamela J. Hornby - Johnson & Johnson (United States)Wei HE - Johnson & Johnson (United States)
- Publication Details
- Journal of medicinal chemistry, v 49(11), pp 3402-3411
- Publisher
- American Chemical Society; WASHINGTON
- Number of pages
- 10
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology; Neurobiology and Anatomy; Pharmacology and Physiology
- Web of Science ID
- WOS:000237832400042
- Scopus ID
- 2-s2.0-33744798761
- Other Identifier
- 991021931907504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Chemistry, Medicinal